Will SKINBIOTHERAPEUTICS stock go up?

According to Danelfin AI, SKINBIOTHERAPEUTICS has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (47.67%) is -2.01% vs. the average probability (49.69%) of all European stocks.

Is it a good time to buy, sell, or hold SKINBIOTHERAPEUTICS stock right now?

SKINBIOTHERAPEUTICS has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (47.67%) is -2.01% vs. the average probability (49.69%) of all European stocks, based on our AI-powered analysis. You can find more details on whether SKINBIOTHERAPEUTICS stock is a good buy .

What is going on with SKINBIOTHERAPEUTICS stock in the last 3 months?

The SKINBIOTHERAPEUTICS stock performance in the last quarter has been -.

Does SKINBIOTHERAPEUTICS offer dividend payments?

No, SKINBIOTHERAPEUTICS does not currently pay dividends.

What is the current market capitalization of SKINBIOTHERAPEUTICS?

SKINBIOTHERAPEUTICS's market cap is GBX 27.21M, as of 2026-07-02 08:00.

SkinBioTherapeutics PLC (SBTX.L) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

SBTX.L AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score

Hold

SKINBIOTHERAPEUTICS (SBTX.L) has an AI Score of 5/10 (Hold) because, according to an overall analysis, it has a probability advantage of -2.01% of beating the market (STOXX 600) in the next 3 months. This advantage is calculated as the difference between the average probability of any European stock (49.69%) and the probability of SBTX.L (47.67%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any European stock of beating the market (3M)49.69%
SBTX.L probability advantage of beating the market (3M)-2.01%
SBTX.L probability of beating the market (3M)47.67%

SBTX.L probability advantage of beating the market (3M): -2.01%

The AI-powered overall analysis of SKINBIOTHERAPEUTICS (SBTX.L) is based on the 0 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 24 months (alpha signals). These alpha signals explain the probability advantage of SBTX.L:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
-	-	-	-	-

SBTX.L probability advantage of beating the market (3M)Total:-2.01%
SBTX.L AI Score

Significant changes Vs previous day

SBTX.L Trading Parameters

Trading parameters are unavailable for SBTX.L.

SBTX.L Frequently Asked Questions

Will SKINBIOTHERAPEUTICS stock go up?
According to Danelfin AI, SKINBIOTHERAPEUTICS has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (47.67%) is -2.01% vs. the average probability (49.69%) of all European stocks.
Is it a good time to buy, sell, or hold SKINBIOTHERAPEUTICS stock right now?
What is going on with SKINBIOTHERAPEUTICS stock in the last 3 months?
Does SKINBIOTHERAPEUTICS offer dividend payments?
What is the current market capitalization of SKINBIOTHERAPEUTICS?

SkinBioTherapeutics PLC Company Profile

SKINBIOTHERAPEUTICS PLC (SBTX.L) is a biopharmaceutical company focused on developing innovative treatments for a range of skin conditions. It applies advanced scientific research to address significant unmet medical needs within the field of dermatology. The company's primary objective involves creating novel solutions that enhance overall skin health and restore proper skin function. Its work centers on understanding and leveraging the skin's natural biological processes and its intricate ecosystem.

A central component of the company's scientific approach is its proprietary SkinBiotix® platform technology. This platform is specifically designed to modulate the skin microbiome. The microbiome plays a crucial and complex role in maintaining skin health and influencing various skin diseases. By harnessing the power of beneficial microorganisms, SkinBiotix® aims to restore microbial balance and improve the skin's protective barrier function. This foundational technology supports the development of a pipeline of novel therapeutic candidates for diverse dermatological applications.

SKINBIOTHERAPEUTICS PLC applies its microbiome technology across multiple therapeutic and consumer health domains. In the therapeutic space, it develops specific candidates for inflammatory skin conditions, including chronic conditions like psoriasis and atopic dermatitis. An example is AxisBiotix-Ps™, a product candidate formulated to help manage the symptoms associated with psoriasis. Beyond therapeutics, the company engages in strategic collaborations with established industry partners to integrate its technology into cosmetic and consumer skincare products. These partnerships aim to bring microbiome-based solutions to a broader market for daily skin maintenance, protection, and improvement.

The company's target customers include patients seeking advanced dermatological treatments and healthcare professionals prescribing these innovative therapies. It also collaborates with pharmaceutical and consumer goods companies for product development, co-marketing, and market access. SKINBIOTHERAPEUTICS PLC generates revenue through product sales, intellectual property licensing agreements, and royalties derived from its technology platform. Its go-to-market strategy combines direct engagement with medical and scientific communities with strategic partnerships for distribution and commercialization, establishing a presence across international markets.

Sector:Health Care
Country:United Kingdom
Industry:
Address:The Core, Newcastle Helix, Newcastle upon Tyne
Employees:41
Website:skinbiotherapeutics.com

Pros

Proprietary microbiome technology platform

Expanding consumer interest in microbiome-based products

Potential for high operating leverage from licensing

Broad application potential across skin health segments

Lower regulatory barriers for cosmetic and device applications

Cons

High capital intensity for research and development

Reliance on successful clinical trial outcomes

Competition from large established skincare companies

Concentration of business on a single core technology

Uncertainty of market adoption for novel solutions

Pros

Cons

Company	AI Score	Compare
OPTI.LOptiBiotix Health PLC

Company

AI Score

Compare

OPTI.LOptiBiotix Health PLC

Company

AI Score

Compare

SBTX.L Top 10 Industry Stocks

Biotechnology

	Company	AI Score	Compare
1	PHM.MCPharma Mar SA
2	ARBS.MIArterra Bioscience SpA
3	KURN.SWKuros Biosciences AG
4	BSLN.SWBasilea Pharmaceutica AG Allschwil
5	ALERS.PAEurobio Scientific SA
6	AZT.OLArcticzymes Technologies ASA
7	BIOA B.STBioArctic AB
8	RDG.WARead Gene SA
9	RTALB.E.ISRTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret AS
10	VLA.PAValneva SE

	Company	AI Score	Compare

SBTX.L Top 10 Sector Stocks

Health Care

	Company	AI Score	Compare
1	REC.MIRecordati Industria Chimica e Farmaceutica SpA
2	FAE.MCFaes Farma SA
3	ALK B.COALK-Abello A/S
4	ANCR.LAnimalcare Group plc
5	LKMNH.E.ISLokman Hekim Engurusag Saglik Turizm Egitim Hizmetleri ve Insaat Taahhut AS
6	LAB.MCLabiana Health SA
7	TNZTP.E.ISTapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS
8	MPARK.E.ISMLP Saglik Hizmetleri AS
9	PRM.MCPrim SA
10	AEVS.SWAevis Victoria SA

	Company	AI Score	Compare

SBTX.L Stock AI Analysis High Risk